Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

por Laé, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., Vieillefond, A.
Publicado 2010

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

por Pierga, J. Y., Lainé-Bidron, C., Beuzeboc, P., De Crémoux, P., Pouillart, P., Magdelénat, H.
Publicado 1997

1718P A French experience on COVID-19 and cancer from an academic general hospital in Paris area

por Laurain, P.A., Landrin, T., Benmaziane Teillet, A., Sekkate, S., Billard, D., Lesprit, P., Couderc, L-J., Friard, S., Doubre, H., Beuzeboc, P., Ratta, R.
Publicado 2020

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90...

por Pierga, J. Y., Jouve, M., Asselain, B., Livartowski, A., Beuzeboc, P., Diéras, V., Scholl, S., Dorval, T., Palangié, T., Garcia-Giralt, E., Pouillart, P.
Publicado 1998

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

por Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Publicado 2000